Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.L'invention concerne des tétrahydroisoquinolines [1,2,4]triazolo[l,5-α]pyridinyl-6-yl substitués. Ces composés et les formes cristallines SA1 et N-2 sont utilisés pour traiter des troubles neurologiques et physiologiques variés. L'invention concerne également des procédés de production de ces composés et des formes cristallines SA-1 et N-2.